| May 22 2015 |
Second Circuit Affirms Preliminary Injunction in Antitrust Suit Against Drug Companies for "Product Hopping" |
American University Washington College of Law |
| May 22 2015 |
UPDATE: Ice Cream Recall Begets First Lawsuit |
ArentFox Schiff LLP |
| May 21 2015 |
Life Sciences Congressional Investigations: Trends, Traps and Tips |
Tycko & Zavareei LLP |
| May 21 2015 |
Apotex Petitions Supreme Court to Review Therasense Standards |
Schwegman, Lundberg & Woessner, P.A. |
| May 21 2015 |
Patent Safe Harbor Applies To Supplemental New Drug Applications |
Foley & Lardner LLP |
| May 20 2015 |
Maker’s Marketing: Bourbon Distiller Racks up “Handmade” False Advertising Victory |
Proskauer Rose LLP |
| May 20 2015 |
Alcohol Tax Breaks Brewing In Congress - May 2015 |
McBrayer, McGinnis, Leslie and Kirkland, PLLC |
| May 19 2015 |
Private Lives v Saving Lives: Privacy Intrusions Of Little Consequence When Drug Testing in Australia |
Squire Patton Boggs (US) LLP |
| May 19 2015 |
Federal Circuit Finds No Direct Infringement Of Akamai Patents |
Foley & Lardner LLP |
| May 18 2015 |
The Sixth Circuit Reins in the Government's Measure of False Claims Act Damages |
Katten |
| May 18 2015 |
Are Cosmetics Gaining Higher Congressional and FDA Scrutiny? |
Mintz |
| May 14 2015 |
FDA Issues Guidance for Mobile Medical Apps |
McBrayer, McGinnis, Leslie and Kirkland, PLLC |
| May 14 2015 |
More Biosimilar Q&A’s Released by FDA - Food and Drug Administration |
Mintz |
| May 14 2015 |
Maker’s Mark Defeats “Handmade” Class Action Lawsuit |
McDermott Will & Emery |
| May 14 2015 |
Employer’s Use of DNA Test to Catch Employee Engaging in Inappropriate Workplace Behavior Violates Federal Law |
Mintz |
| May 14 2015 |
FDA Issues Final Guidance on Biosimilars |
ArentFox Schiff LLP |
| May 14 2015 |
First Look At False Marking Under The AIA - America Invents Act |
Foley & Lardner LLP |
| May 12 2015 |
FDA Releases Additional Guidelines for Biosimilars |
ArentFox Schiff LLP |
| May 12 2015 |
California Supreme Court Scrutinizes Reverse Payment ANDA Settlements |
Foley & Lardner LLP |
| May 11 2015 |
FDA Releases Draft Guidance on Using Clinical Data from Studies Conducted Outside the United States to Support Approval of Medical Devices |
Barnes & Thornburg LLP |
| May 11 2015 |
Amarin Pharma Preemptively Sues FDA over First Amendment Rights |
Barnes & Thornburg LLP |
| May 8 2015 |
Purdue Pharma v. Depomed: Denying Request for Rehearing Decision on Institution IPR2014-00379 |
Faegre Drinker |
| May 8 2015 |
CMS Issues Interim Final Rule Reaffirming Requirements for Prescribers of Part D Drugs |
McDermott Will & Emery |
| May 7 2015 |
CMS Amends Medicare Part D Program Integrity Regulations to Facilitate Beneficiary Access and Expand Coverage for Pharmacist Prescribers |
Epstein Becker & Green, P.C. |
| May 7 2015 |
A Court in the Sunshine State Blocks Injunctive Relief against Neutrogena Sunscreen Claims; Meanwhile P&G Cannot Flush Charmin Claims for the Same Relief in New York |
Proskauer Rose LLP |
| May 7 2015 |
340B ‘Mega-Guidance’ Arrives at Office of Management and Budget |
McDermott Will & Emery |
| May 6 2015 |
Study Suggests Skin Cancer Drug May Help Treat Mesothelioma and Lung Cancers |
Steptoe & Johnson PLLC |
| May 6 2015 |
FDA Issues Draft Guidance on Determining when Data from Foreign Clinical Studies Can Support Device Submissions |
Covington & Burling LLP |
| May 6 2015 |
Federal Circuit Keeps Sandoz Biosimilar Off The Market For Now |
Foley & Lardner LLP |
| May 5 2015 |
Keeping Up With Kyle Bass: Pharma Patents Post |
Foley & Lardner LLP |
| May 1 2015 |
FDA Finalizes Guidance Documents on Biosimilarity |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| May 1 2015 |
Onward to Trial: Federal Court Rejects Vermont’s Motion to Dismiss GMA Lawsuit |
Mintz |
| May 1 2015 |
Petitioners Must Present Sufficient Evidence to Establish Inherency |
Mintz |
| Apr 30 2015 |
Tomorrow is Another One-A-Day: FDA Guidelines Preempt Vitamin Claims, but Consumer Class Still Has Opportunity to Supplement |
Proskauer Rose LLP |
| Apr 30 2015 |
Why the Grace Period Restoration Act Is a Bad Idea |
Foley & Lardner LLP |
